Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.

ABSTRACT:

Background

Dactinomycin (AMD) and vincristine (VCR) have been used for the treatment of childhood cancer over the past 40 years but evidence-based dosing guidance is lacking.

Methods

Patient AMD and VCR dose and drug-related adverse event (AE) information from four rhabdomyosarcoma (RMS) and two Wilms tumor (WT) studies were assembled. Statistical modeling was used to account for differences in AE data collection across studies, develop rate models for grade 3/4 CTCAE v3 hepatic- (AMD) and neuro- (VCR) toxicity, assess variation in toxicity rates over age and other factors, and predict toxicity risk under current dosing guidelines.

Results

For the same dose/body size, AMD toxicity rates were higher in patients <1 year than older patients and VCR toxicity rates increas

SUBMITTER: Langholz B 

PROVIDER: S-EPMC3467305 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature